Form 4: Pfizer CEO Bourla Acquires Phantom Stock Units
Insider Transaction Report
Pfizer Chairman and CEO Albert Bourla acquired 24 phantom stock units through a deferred compensation plan, increasing his beneficial ownership.
Summary
- Albert Bourla, Chairman & CEO of Pfizer Inc. (PFE), reported an acquisition of derivative securities.
- On October 31, 2025, Mr. Bourla acquired 24 phantom stock units.
- These units were acquired at a price of $24.65 per unit.
- The acquisition was made pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan.
- Following this transaction, Mr. Bourla beneficially owns 731,108 derivative securities.
- Each phantom stock unit represents one phantom share of common stock and is settled in cash upon separation from service, and may be transferred into an alternative investment account.
Sentiment
Score: 6
Explanation: The acquisition of phantom stock units by the CEO, even in a small quantity, generally indicates continued alignment with the company's long-term performance and participation in its compensation plans. It is not a direct open-market purchase but a plan-based acquisition, thus slightly positive.
Positives
- Chairman & CEO Albert Bourla acquired 24 phantom stock units, indicating continued participation in the company's deferred compensation plan.
- The acquisition demonstrates alignment of management's interests with long-term company performance through participation in equity-linked plans.
Future Outlook
N/A. This filing reports an insider transaction and does not provide forward-looking statements or guidance.
Industry Context
N/A. This filing pertains to an individual insider transaction and does not provide broader industry context or trends.
Related Party Transactions
- The acquisition of 24 phantom stock units by Chairman & CEO Albert Bourla was made pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, which is a company-sponsored program for insiders.
Stakeholder Impact
- Shareholders: Minimal direct impact due to the small number of units involved, but it signals continued management participation in company-sponsored plans.
- Employees: No direct impact mentioned.
Key Dates
| Date | Description |
|---|---|
| 10/31/2025 | Date of transaction for the acquisition of phantom stock units. |
| 11/03/2025 | Date the Form 4 was signed and filed. |
Keywords
Pfizer, PFE, Albert Bourla, Insider Transaction, Form 4, Phantom Stock Units, Deferred Compensation, CEO Stock Acquisition
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.